Randomized controlled study comparing vitamin D and omega 3-fatty acids supplementation in adolescents with polycystic ovary syndrome

Flora Bacopoulou1, Evangelia Kolas1, Leon Aravantinos1, Aimilia Mantzon1, Artemis Doulgeraki2, Fillo Spanouli1, Efthimios Deligeorgoul2, Evangelia Charmandari2

1. Center for Adolescent Medicine and UNESCO Chair on Adolescent Health Care, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Aghia Sophia Children’s Hospital, Greece
2. Second Department of Obstetrics and Gynecology, University of Athens Medical School, Greece
3. Unit of Translational and Clinical Research in Endocrinology, Athens University Medical School, Athens, Greece
4. Department of Bone and Mineral Metabolism, Institute of Child Health, Aghia Sophia Children’s Hospital, Athens, Greece
5. Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, University of Athens Medical School, Aghia Sophia Children’s Hospital, Greece

Background: Polycystic ovary syndrome (PCOS) is a complex endocrine genetic disorder, associated with increased metabolic and cardiovascular morbidity. Vitamin D or omega-3 fatty acids supplementation may alleviate the metabolic and reproductive complications of PCOS. Evidence is limited regarding vitamin D supplementation in adolescents with PCOS.

Objective and hypotheses: To compare clinical, psychometric, biochemical, endocrine, bone and sonographic markers in vitamin D sufficient adolescents with PCOS, pre- and post- 6 month intervention with vitamin D or eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation.

Methods: Prospective study of adolescents aged 14-18 years with PCOS diagnosed according to Rotterdam criteria and Vitamin D sufficiency (25OHD ≥ 30ng/mL)
Exclusion criteria: severe chronic disease, chronic medication, use of contraceptives or dietary supplements.
Both at baseline and post-intervention, participants underwent detailed clinical, biochemical, endocrine, sonographic and psychometric evaluation, 3-hour OGTT for glucose and insulin, measurement of bone density and body composition by DEXA.
Subsequently, they were randomized into 3 groups:
- Vitamin D (D) group received 2,000 IU D3 daily
- Omega-3 fatty acids (Ω3) group received 1 g EPA & DHA daily
- Control (C) group received no treatment

Results: Study participants included 30 adolescents (mean age 15.7 ± 2.1 years), 11 in D-group, 10 in Ω3-group and 9 in C-group.
No statistically significant differences among groups in adolescents’ clinical and anthropometric measures, ovarian volumes, hsCRP, IL-6, AUCc and AUCt for glucose and insulin, body composition and perceived stress scale-14 score.
Post-intervention and compared with the control group:
D-group had significantly increased serum DHEA (p=0.044), DHEAS (p=0.017) and endometrial thickness (p=0.002)
Ω3-group had significantly decreased serum 25OHD (p=0.007) and PTH (p=0.043) and increased LDL (p=0.046), ApoB (p=0.023) and number of menses (p=0.046)

Conclusion: In adolescents with PCOS, improvement of the menstrual cycle was noted in the group treated with omega-3 fatty acids. There was no improvement in the metabolic profile of patients in either group.

Authors report no conflicts of interest